Osicent (Osimertinib) 80 mg Tablets
Osicent 80 mg (Osimertinib) is a third-generation EGFR tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC).
Manufacturer: Incepta Pharmaceuticals. Each pack contains 30 tablets. It is designed to inhibit both EGFR-sensitizing and EGFR T790M-resistance mutations, effectively blocking tumor growth.
Key Feature:
Osimertinib crosses the blood-brain barrier, showing significant efficacy against central nervous system (CNS) metastases.
Indicated for the treatment of adult patients with metastatic NSCLC:
- 🔹 First-line treatment: Patients whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.
- 🔹 Second-line treatment: Patients with EGFR T790M mutation-positive NSCLC (detected after progression on prior EGFR TKI therapy).
- 🔹 Adjuvant therapy: After tumor resection in patients with EGFR mutation-positive NSCLC.
Packaging: 80 mg tablets.
⚠️ ADMINISTRATION PROTOCOL:
- Recommended Dose: 80 mg orally once daily.
- Timing: Take at the same time each day, with or without food.
- Administration: Swallow the tablet whole with water. Do not crush, split, or chew.
- For Difficulty Swallowing: The tablet can be dispersed in 50 mL of non-carbonated water (stir until dispersed, do not crush) and swallowed immediately.
- Hypersensitivity to Osimertinib.
- Pregnancy and breastfeeding (embryo-fetal toxicity).
- History of Interstitial Lung Disease (ILD) or drug-induced pneumonitis.
- Concomitant use with St. John's Wort.
Common adverse reactions include:
- 🩸 Cardiac/Labs: QT interval prolongation, decreased leukocytes/platelets.
- 📉 Dermatologic: Rash, dry skin, paronychia (nail infection/inflammation), pruritus.
- 🌀 Respiratory/GI: Diarrhea, stomatitis, interstitial lung disease (ILD) — requires immediate medical attention.
- Patients should monitor for nail changes and skin rash regularly.
Similar products
What Customers Say
No reviews yet
Your review can be the first!